Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency

European Journal of Pediatrics

Volumn 173, Issue 12, 2014, Pages 1639-1642

  Butwicka, Agnieszka ^a,b   Krystyna, Szymańska ^b   Retka, Włodzimierz ^b   Wolańczyk, Tomasz ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adverse drug reactions; CYP2D6; Neuroleptic malignant syndrome; Pharmacogenetics; Poor metabolizer

Indexed keywords

EID: 84887603385     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-013-2208-z     Document Type: Article

References (11)

1. Clavenna A, Rossi E, DeRosa M, Bonati M (2007) Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 166(4):339–347. doi:10.1007/s00431-006-0244-7
2. Croarkin PE, Emslie GJ, Mayes TL (2008) Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 69(7):1157–1165
3. Fang J, Baker GB, Silverstone PH, Coutts RT (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17(2):227–233
4. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195–235. doi:10.1055/s-0031-1286287
5. Jarventausta K, Leinonen E (2000) Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand 102(3):231–233
6. Kato D, Kawanishi C, Kishida I, Furuno T, Suzuki K, Onishi H, Hirayasu Y (2007) Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 63(11):991–996. doi:10.1007/s00228-007-0355-8
7. Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004) Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol Psychiatry 9(3):293–298. doi:10.1038/sj.mp.4001422
8. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG (2002) Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 26(5):897–902
9. Luchini F, Lattanzi L, Bartolommei N, Cosentino L, Litta A, Kansky C, Mauri M, Cassano GB, Fagiolini A, Casamassima F (2013) Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Four case reports. J Nerv Ment Dis 201(1):36–42. doi:10.1097/NMD.0b013e31827ab24b
10. Soutullo CA, Cottingham EM, Keck PE Jr (1999) Psychosis associated with pseudoephedrine and dextromethorphan. J Am Acad Child Adolesc Psychiatry 38(12):1471–1472. doi:10.1097/00004583-199912000-00004
11. van Maidegem BT, Smit LME, Touw DJ, Gemke RJBJ (2002) Neuroleptic malignant syndrome in a 4-year-old girl associated with alimemazine. Eur J Pediatr 161(5):259–261. doi:10.1007/s00431-002-0956-2